Phase IIB Grant to Fund Commercialization Activities for the Quantra DxTM Platform
Charlottesville, VA – March 10, 2015 – HemoSonics, a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding, today announced that it received a $2 million Phase IIB grant from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to commercialize the Quantra Dx™ system. The Phase IIB grant will help fund the completion of design for manufacturing under a quality control environment, regulatory trials, and regulatory submissions in the US and Europe.
“This grant validates the need for a fast and accurate point-of-care instrument to guide the selection and dosing of blood products in critical bleeding situations,” said Francesco Viola Chief Science Officer of HemoSonics. “These funds will support development the Quantra Dx™ platform, which is designed to enable more targeted selection and dosing of blood products in critical care settings.”